Live Breaking News & Updates on கெட்டமைன் உட்செலுத்துதல் மையங்கள்|Page 3

Stay updated with breaking news from கெட்டமைன் உட்செலுத்துதல் மையங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Delic's Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations


Delic s Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations
News provided by
Share this article
VANCOUVER, BC, May 11, 2021 /PRNewswire/ -
Company ) (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021),
Ketamine Infusion Centers ( KIC ), proposes to acquire two (2) additional licensed ketamine clinics in Arizona. The proposed acquisition would double the footprint of the infusion chain and become the largest operator in the state of Arizona.
This is a major step toward becoming the largest ketamine clinic operator in the country, bringing superior quality and expanding access for patients, said Matt Stang, Delic CEO and co-founder. KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly ....

United States , State Of Arizona , British Columbia , Rogelio Monzon , Sonny Diaz , Christopher Ray , Matt Stang , Ganesh Acharya , Delic Holdings Inc , Ketamine Infusion Centers , Health Canada , Canadian Securities Exchange , Double Chain , Cement Largest Clinic , Infusion Centers , Central Phoenix , East Valley , West Valley , Biotech Discovery Ventures , Looking Information , United States Private Securities , Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , நிலை ஆஃப் அரிசோனா , பிரிட்டிஷ் கொலம்பியா , ரொகீலியோ மொந்ஸாந் ,

From High Times, to facing prison, Matt Stang is now the CEO of a psychedelic company


From High Times, to facing prison, Matt Stang is now the CEO of a psychedelic company
Stang says he lived through the tipping point with cannabis and something similar is happening with psychedelics.
Author of the article: Sam Riches
Publishing date: May 03, 2021  •  4 hours ago  •  5 minute read
Matt and Jackee Stang, the co-founders of Delic Corp. Photo by Delic Corp
Article content
This story first appeared in Weekend Dispensary, a weekly newsletter from The GrowthOp. Signup now to get a story delivered to your inbox every Saturday. 
In 2010, Matt Stang was facing the possibility of spending the rest of his life in prison. ....

New York , United States , Comunidad Autonoma De Cataluna , Jackee Stang , Kenzi Riboulet Zemouli , Albert Hofmann , Matt Stang , Jim Hayes , Preet Bharara , Kareem Burke , Postmedia Network Inc , Ketamine Infusion Centers , Multidisciplinary Association For Psychedelic Studies , Delic Corp , Health Canada , Us Department Of Justice , Canadian Securities Exchange , From High Times , Weekend Dispensary , High Times , Operation Green , Roca Fella Rec , New York City , Magazine Guy , Homeland Security Investigations , Sagen Sour ,

How to Invest in | The Kingston Whig Standard


Article content
Let’s take a look at how investors can add exposure to the psychedelics sector and add into their portfolio without having to purchase multiple companies and actively manage their portfolio.
Invest in a Psychedelics ETF
Exchange-traded funds, or ETFs, are one of the easiest ways for investors to build exposure to different corners of the market into their portfolios. They provide instant diversification to a particular theme with exposure to many different stocks in a single security. At the same time, passive ETFs are typically less expensive to own than actively managed mutual funds.
The Horizons Psychedelic Stock Index ETF became the first exchange-traded fund in Canada to focus on psychedelics with its launch in January. With exposure to 23 publicly traded psychedelics companies, a single share of the ETF provides broad exposure to the entire psychedelics industry with a modest 0.85% expense ratio. ....

United States , Johns Hopkins , Paul Rosen , Pharmacan Capital Corp , Delic Holdings Inc , Seelos Therapeutics Inc , Delic Corp , Exchange Commission , Medicine Inc , Delic Holding , Newsfile Corp , Johnson Inc , Enterprises Inc , Ketamine Infusion Centers , Warren Buffett Berkshire Hathaway Inc , Abbvie Inc , Delic Holdings , Seelos Therapeutics , Mind Medicine , Compass Pathways , Warren Buffett , Berkshire Hathaway Inc , High Times , Pharmacan Capital , Complex Biotech Diversity Ventures , Media Contact ,